The DEA (the US Drug Enforcement Administration, which controls what drugs are legal) is very unlikely to start a formal review of psilocybin's status as a banned substance in the next three months. This matters because rescheduling — moving psilocybin off the most restricted drug list — is the main legal barrier stopping doctors from prescribing it widely. Without a DEA review, that barrier stays in place.
No congressional mandate is moving; DEA acts on statute and evidence, not pilot studies or advocacy.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →